RAPT Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
122
- Stock Symbol
-
RAPT
- Share Price
-
$15.11
- (As of Tuesday Closing)
RAPT Therapeutics General Information
Description
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Contact Information
- 561 Eccles Avenue
- South San Francisco, CA 94080
- United States
RAPT Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.11 | $15.99 | $14.96 - $31.45 | $550M | 34.4M | 289K | -$2.69 |
RAPT Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 419,149 | 484,936 | 874,441 | 362,180 |
| Revenue | 0 | 1,527 | 3,813 | 5,042 |
| EBITDA | (97,657) | (82,791) | (68,208) | (50,779) |
| Net Income | (98,737) | (83,838) | (69,204) | (52,892) |
| Total Assets | 220,756 | 266,209 | 198,636 | 118,969 |
| Total Debt | 7,998 | 8,990 | 0 |
RAPT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RAPT Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
RAPT Therapeutics Comparisons
Industry
Financing
Details
000000
0000 0
RAPT Therapeutics Competitors (60)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnaptysBio | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 0000 | 00000 | 000000&0 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Maastricht, Netherlands | 0 | 000.00 | 00000 00000 | 000.00 |
RAPT Therapeutics Patents
RAPT Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220305018-A1 | Pyrazole pyrimidine compounds and uses thereof | Pending | 15-Mar-2021 | 0000000000 | |
| AU-2022216216-A1 | Methods of making trans isomeric forms of g protein-coupled receptor modulators | Pending | 02-Feb-2021 | 0000000000 | |
| CA-3209122-A1 | Methods of making trans isomeric forms of g protein-coupled receptor modulators | Pending | 02-Feb-2021 | 0000000000 | |
| US-20220251070-A1 | Methods of making trans isomeric forms of g protein-coupled receptor modulators | Pending | 02-Feb-2021 | 0000000000 | 0 |
| AU-2020383625-A1 | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof | Pending | 13-Nov-2019 | C07D487/04 |
RAPT Therapeutics Executive Team (13)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Brian Wong Ph.D | Chief Executive Officer & Board Member | ||
| Rodney Young | Chief Financial Officer | ||
| Gwen Carscadden | Chief Human Resources Officer | ||
| Dirk Brockstedt Ph.D | Chief Scientific Officer | ||
| David Wustrow Ph.D | Senior Vice President, Discovery and Preclinical Development |
RAPT Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alexander Rudensky Ph.D | Self | Chairman & Advisor | 000 0000 |
| Brian Wong Ph.D | RAPT Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Linda Kozick | RAPT Therapeutics | Board Member | 000 0000 |
| Mary Gray Ph.D | Self | Board Member | 000 0000 |
| Michael Giordano MD | RAPT Therapeutics | Board Member | 000 0000 |
RAPT Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
RAPT Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
RAPT Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2023
26.61 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,491
Rank
Percentile
Pharmaceuticals
Industry
00 of 871
Rank
Percentile
Biotechnology
Subindustry
00 of 389
Rank
Percentile
